https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-352012-08-19 00:00:002019-02-15 09:22:38The use of oncolytic viruses to overcome lung cancer drug resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-302012-08-01 00:00:002019-02-15 09:21:33Newcastle disease virus: a promising agent for tumour immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):352012-08-01 00:00:002012-08-01 00:00:00Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-762012-07-18 00:00:002019-02-15 09:21:29Cell-type-specific innate immune response to oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-332012-07-01 00:00:002019-02-15 09:23:09Bugs and drugs: oncolytic virotherapy in combination with chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-412012-07-01 00:00:002019-02-15 09:21:39Recent clinical experience with oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-29 / Appl. Biochem. Biotechnol. 2012 Aug;167(7):2005-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-29 / Appl. Biochem. Biotechnol. 2012 Aug;167(7):2005-222012-05-29 00:00:002019-02-15 09:21:30Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-04-18 / Hum. Gene Ther. 2012 Jul;23(7):700-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-04-18 / Hum. Gene Ther. 2012 Jul;23(7):700-102012-04-18 00:00:002019-02-15 09:21:30Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-08 / Arch. Virol. 2012 Jun;157(6):1011-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-08 / Arch. Virol. 2012 Jun;157(6):1011-82012-03-08 00:00:002012-03-08 00:00:00Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Future Microbiol 2012 Mar;7(3):347-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Future Microbiol 2012 Mar;7(3):347-672012-03-01 00:00:002019-02-15 09:21:32Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
